<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ofloxacin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01165</strong>&#160; (APRD00502)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial <span class="caps">DNA</span> gyrase, halting <span class="caps">DNA</span> replication. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01165/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01165/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01165.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01165.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01165.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01165.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01165.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01165">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>OFLX</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Floxin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Floxstat</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ocuflox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zanocin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/nucleic-acid-synthesis-inhibitors">Nucleic Acid Synthesis Inhibitors</a></li>
<li><a href="/mesh/anti-infective-agents">Anti-Infective Agents</a></li>
<li><a href="/mesh/anti-infective-agents-urinary">Anti-Infective Agents, Urinary</a></li>
<li><a href="/mesh/quinolones">Quinolones</a></li></ul></td></tr><tr><th>CAS number</th><td>82419-36-1</td></tr><tr><th>Weight</th><td>Average: 361.3675<br>Monoisotopic: 361.143784348</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>GSDSWSVVBLHKDQ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Quinolines and Derivatives</td></tr><tr><th>Subclass</th><td>Quinoline Carboxylic Acids</td></tr><tr><th>Direct parent</th><td>Quinoline Carboxylic Acids</td></tr><tr><th>Alternative parents</th><td>Fluoroquinolones; Hydroquinolones; Hydroxyquinolines; Benzoxazines; Hydroquinolines; Pyridinecarboxylic Acids; Alkyl Aryl Ethers; Fluorobenzenes; Piperazines; Diazinanes; Aryl Fluorides; Tertiary Amines; Carboxylic Acids; Enolates; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>dihydroquinolone; hydroxyquinoline; dihydroquinoline; benzoxazine; pyridine carboxylic acid or derivative; pyridine carboxylic acid; fluorobenzene; alkyl aryl ether; 1,4-diazinane; aryl halide; piperazine; benzene; aryl fluoride; pyridine; tertiary amine; polyamine; ether; enolate; carboxylic acid; carboxylic acid derivative; organonitrogen compound; amine; organohalogen; organofluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at at least one position.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.</td></tr><tr><th>Pharmacodynamics</th><td>Ofloxacin is a quinolone/fluoroquinolone antibiotic. Ofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.</td></tr><tr><th>Mechanism of action</th><td>Ofloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division.</td></tr><tr><th>Absorption</th><td>Bioavailability of ofloxacin in the tablet formulation is approximately 98%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>32%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td>Elimination is mainly by renal excretion. Between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Four to eight percent of an ofloxacin dose is excreted in the feces. This indicates a small degree of biliary excretion of ofloxacin.</td></tr><tr><th>Half life</th><td>9 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=5450 mg/kg (orally in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9545</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7862</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7489</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8468</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6386</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9268</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7726</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.7844
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9033
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1639 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8402
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.866
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Ortho mcneil pharmaceutical inc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Akorn inc</li>
<li>Alcon inc</li>
<li>Bausch and lomb inc</li>
<li>Fdc ltd</li>
<li>Hi tech pharmacal co inc</li>
<li>Novex pharma</li>
<li>Pharmaforce inc</li>
<li>Sandoz inc</li>
<li>Daiichi pharmaceutical corp</li>
<li>Apotex inc</li>
<li>Bausch and lomb pharmaceuticals inc</li>
<li>Ortho mcneil janssen pharmaceuticals inc</li>
<li>Dr reddys laboratories ltd</li>
<li>Larken laboratories inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Teva pharmaceuticals usa inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.alcon.com">Alcon Laboratories</a></li>
<li><a href="http://www.allergan.com">Allergan Inc.</a></li>
<li><a href="http://www.americanregent.com">American Regent</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bausch.com">Bausch &amp; Lomb Inc.</a></li>
<li><a href="http://www.cipla.com">Cipla Ltd.</a></li>
<li><a href="http://www.daiichisankyo.com">Daiichi Sankyo</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li><a href="http://www.falconpharma.com">Falcon Pharmaceuticals Ltd.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.hitechpharm.com">Hi Tech Pharmacal Co. Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Novex Pharma</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li>Pacific Pharma Lp</li>
<li><a href="http://www.packpharma.com">Pack Pharmaceuticals</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmaforceinc.com">Pharmaforce Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.santeninc.com">Santen Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Ophthalmic</td><td></td></tr><tr><td>Solution</td><td>Ophthalmic</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01370">Aluminium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01373">Calcium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00258">Calcium Acetate</a></td><td>Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. </td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00529">Foscarnet</a></td><td>Increased risk of convulsions</td></tr><tr><td><a href="/drugs/DB01592">Iron</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00893">Iron Dextran</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01378">Magnesium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01377">Magnesium oxide</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01035">Procainamide</a></td><td>Ofloxacin may increase the effect of procainamide.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00364">Sucralfate</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ofloxacin is initiated, discontinued or if the dose is changed.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>The strong CYP1A2 inhibitor, Ofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ofloxacin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Ofloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01593">Zinc</a></td><td>Formation of non-absorbable complexes</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid high doses of caffeine.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>